Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer

M Janghorban, AS Farrell… - Proceedings of the …, 2014 - National Acad Sciences
M Janghorban, AS Farrell, BL Allen-Petersen, C Pelz, CJ Daniel, J Oddo, EM Langer…
Proceedings of the National Academy of Sciences, 2014National Acad Sciences
The transcription factor c-MYC is stabilized and activated by phosphorylation at serine 62
(S62) in breast cancer. Protein phosphatase 2A (PP2A) is a critical negative regulator of c-
MYC through its ability to dephosphorylate S62. By inactivating c-MYC and other key
signaling pathways, PP2A plays an important tumor suppressor function. Two endogenous
inhibitors of PP2A, I2PP2A, Inhibitor-2 of PP2A (SET oncoprotein) and cancerous inhibitor of
PP2A (CIP2A), inactivate PP2A and are overexpressed in several tumor types. Here we …
The transcription factor c-MYC is stabilized and activated by phosphorylation at serine 62 (S62) in breast cancer. Protein phosphatase 2A (PP2A) is a critical negative regulator of c-MYC through its ability to dephosphorylate S62. By inactivating c-MYC and other key signaling pathways, PP2A plays an important tumor suppressor function. Two endogenous inhibitors of PP2A, I2PP2A, Inhibitor-2 of PP2A (SET oncoprotein) and cancerous inhibitor of PP2A (CIP2A), inactivate PP2A and are overexpressed in several tumor types. Here we show that SET is overexpressed in about 50–60% and CIP2A in about 90% of breast cancers. Knockdown of SET or CIP2A reduces the tumorigenic potential of breast cancer cell lines both in vitro and in vivo. Treatment of breast cancer cells in vitro or in vivo with OP449, a novel SET antagonist, also decreases the tumorigenic potential of breast cancer cells and induces apoptosis. We show that this is, at least in part, due to decreased S62 phosphorylation of c-MYC and reduced c-MYC activity and target gene expression. Because of the ubiquitous expression and tumor suppressor activity of PP2A in cells, as well as the critical role of c-MYC in human cancer, we propose that activation of PP2A (here accomplished through antagonizing endogenous inhibitors) could be a novel antitumor strategy to posttranslationally target c-MYC in breast cancer.
National Acad Sciences